MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the third quarter ended September 30, 2024, after the market close on Thursday, November 7, 2024. The Company's management will discuss the results during a conference call beginning at ...

MENLO PARK, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that a new study titled, Impact of TearCare on Reading Speed in Patients with Dry Eye Disease, has been published in the peerreviewed journal Clinical Ophthalmology. Key study findings reported in the study manuscript inc ...

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 19.35%. A quarter ago, it was expected that this company would post a loss of $0.29 per share when it actually produced a loss of $0.33, delivering a surprise of -13.79%. Over the last four quarters, the company has ...

© 2024 Sight Sciences. All rights reserved. The Sustainability Report includes: Governance Practices: Disclosure of Sight Sciences' governance framework, ethical standards, and commitment to transparency and accountability, including reporting on information security breaches. For additional information and highlights, please see the full Sustainability Report, which can be found here. All Environmental, Social, and Governance ("ESG") practices are overseen by the Company's Nominating and Corporate Governan ...

MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its first Sustainability Report, highlighting the Company's sustainability activities, performance, and results from the last three years. Environmental Initiatives: Details of Sight Sciences' effort ...

Core Insights - Sight Sciences, Inc. announced the twelve-month results from the SAHARA trial, demonstrating the effectiveness of TearCare in treating dry eye disease (DED) compared to Restasis [1][3][11] Study Results - Patients previously treated with Restasis showed clinically meaningful improvements in DED symptoms after switching to TearCare, with benefits lasting for six months post-treatment [2][6] - Phase 2 of the SAHARA trial confirmed that TearCare is effective regardless of prior Restasis treatment, indicating its potential as both a primary and secondary treatment option for DED [3][4] - The trial included 345 subjects in Phase 1 and 163 patients crossed over to TearCare in Phase 2, with significant improvements in tear break-up time (TBUT) and other dry eye measures [4][5] Statistical Findings - TBUT improved by 1.1 seconds at three months and 0.6 seconds at twelve months after switching to TearCare, both statistically significant (p<.001) [8] - Other measures, including meibomian gland secretion score (MGSS) and ocular surface disease index (OSDI), also showed significant improvements post-treatment [8][10] - The study reported that mean values for TBUT, MGSS, and other ocular signs improved significantly compared to baseline measurements [10][11] Future Directions - The SAHARA trial will continue into Phase 3, which aims to provide long-term data on the durability and effectiveness of TearCare over a two-year period [11]

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the publication of the twelve-month results from the SAHARA trial. Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops ("Restasis") had additional ...

Core Insights - Sight Sciences, Inc. announced new findings from the ROMEO study, indicating that the OMNI Surgical System is effective in treating advanced glaucoma patients, challenging previous beliefs about treatment efficacy in severe cases [1][2][3] Group 1: Study Findings - The analysis showed that ab interno canaloplasty combined with trabeculotomy using OMNI effectively lowered intraocular pressure (IOP) and reduced medication usage across all glaucoma severity stages [2][3] - Significant reductions in IOP and IOP-reducing medications were observed, with 70% of eyes experiencing IOP reduction at Month 12, and 92% achieving levels of 18 mmHg or less [7] - The mean IOP at Month 12 ranged between 14 mmHg and 16 mmHg across severity groups, indicating consistent treatment outcomes [7] - Medication reductions were noted in 50% to 69% of patients, with the majority showing a reduction of at least one medication [7] - Regression analysis indicated no significant relationship between Month 12 IOP and visual field loss, suggesting treatment effectiveness is independent of disease severity [7] Group 2: Company Overview - Sight Sciences is focused on developing innovative eyecare technologies aimed at transforming patient care and improving lives, particularly through minimally invasive procedures [1][8] - The OMNI Surgical System is FDA-cleared for reducing IOP in adult patients with primary open-angle glaucoma, and it is CE Marked for additional procedures [8] - The company also offers the TearCare System for treating evaporative dry eye disease and the SION Surgical Instrument for ophthalmic surgeries [8]

Core Insights - Sight Sciences, Inc. announced new findings from the ROMEO study, indicating that the OMNI Surgical System is effective in treating advanced glaucoma patients, challenging previous beliefs about treatment efficacy in severe cases [1][2][3] Group 1: Study Findings - The analysis showed that ab interno canaloplasty combined with trabeculotomy using OMNI effectively lowered intraocular pressure (IOP) and reduced medication usage across all severity levels of glaucoma [2][5] - 70% of eyes experienced a reduction in IOP at 12 months, with 92% achieving IOP levels of 18 mmHg or less [5] - The mean IOP at month 12 ranged between 14 mmHg and 16 mmHg, consistent across different severity groups [5] - A significant percentage of patients (50% to 69%) showed a reduction of at least one medication, indicating the treatment's effectiveness [5] - Regression analysis indicated no significant relationship between month 12 IOP and visual field loss, suggesting consistent treatment outcomes regardless of disease severity [5] Group 2: Study Design and Demographics - The ROMEO study was a retrospective case series approved by an Institutional Review Board, conducted at eleven ophthalmology practices in the U.S. [3] - The majority of participants (95%) had primary open-angle glaucoma and underwent the implant-free OMNI procedure, which is FDA-cleared for canaloplasty and trabeculotomy [3][4] Group 3: Company Vision and Technology - Sight Sciences aims to transform eyecare through innovative, minimally invasive technologies that address the underlying causes of prevalent eye diseases [8] - The OMNI Surgical System is indicated for reducing IOP in adult patients with primary open-angle glaucoma and is CE marked for additional procedures [8] - The company is committed to providing effective treatment options for glaucoma patients at all disease stages, reinforcing its dedication to advancing eyecare technology [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-40587 SIGHT SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 80-0625749 (St ...